Literature DB >> 20119823

Neuroprotective effect of carvedilol and melatonin on 3-nitropropionic acid-induced neurotoxicity in neuroblastoma.

I Tasset1, C Espínola, F J Medina, M Feijóo, C Ruiz, E Moreno, M M Gómez, J A Collado, C Muñoz, J Muntané, P Montilla, I Túnez.   

Abstract

In neurodegenerative diseases, progressive oxidative stress is a major event that precedes neuronal death. Oxidative stress is characterized by an imbalance between oxidants and antioxidants. This imbalance induced oxidative molecular and cell damage, reducing cellular viability. 3-Nitropropionic acid (3NP) causes oxidative stress and other molecular and cellular changes similar to those observed in neurons of patients with Huntington's disease. Since carvedilol and melatonin act as free-radical scavengers, this study examined the effect of carvedilol (10(-5) M) and melatonin (10(-5) M) on oxidative and cell damage induced by 3NP in N1E-115 neuroblastoma cells. Carvedilol and melatonin prevented the increases in lipid peroxidation and total LDH activity, as well as the depletion of reduced glutathione (GSH) and the reduction of antioxidative enzymes activities in N1E-115 cells incubated with 100 mM 3NP. All these carvedilol and melatonin effects were more intense when the drugs were added before rather than after inducing the damage by 3NP. These results also provided evidence supporting the hypothesis that carvedilol and melatonin can be useful for treating neurodegenerative diseases, such as Huntington's disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20119823     DOI: 10.1007/BF03180581

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  23 in total

1.  Effect of nicotine on 3-nitropropionic acid-induced oxidative stress in synaptosomes.

Authors:  Isaac Túnez; Pedro Montilla; M Carmen Muñoz; René Drucker-Colín
Journal:  Eur J Pharmacol       Date:  2004-11-19       Impact factor: 4.432

Review 2.  [Model of Huntington's disease induced with 3-nitropropionic acid].

Authors:  I Túnez; A Santamaría
Journal:  Rev Neurol       Date:  2009 Apr 16-30       Impact factor: 0.870

Review 3.  3-Nitropropionic acid animal model and Huntington's disease.

Authors:  C V Borlongan; T K Koutouzis; P R Sanberg
Journal:  Neurosci Biobehav Rev       Date:  1997-05       Impact factor: 8.989

4.  Protective effect of carvedilol on oxidative stress induced by okadaic acid in N1E-115 cells.

Authors:  Isaac Túnez; Juan A Collado; Francisco J Medina; M Carmen Muñoz; Rafael Gordillo; Concepción Sampedro; María J Moyano; Montserrat Feijóo; Jordi Muntané; Pedro Montilla
Journal:  Pharmacol Res       Date:  2006-06-06       Impact factor: 7.658

5.  Catalase in vitro.

Authors:  H Aebi
Journal:  Methods Enzymol       Date:  1984       Impact factor: 1.600

6.  Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington's disease or chronic brain injury.

Authors:  J Christofides; M Bridel; M Egerton; G M Mackay; C M Forrest; N Stoy; L G Darlington; T W Stone
Journal:  J Neurochem       Date:  2006-03-29       Impact factor: 5.372

7.  Melatonin increases gene expression for antioxidant enzymes in rat brain cortex.

Authors:  M Kotler; C Rodríguez; R M Sáinz; I Antolín; A Menéndez-Peláez
Journal:  J Pineal Res       Date:  1998-03       Impact factor: 13.007

8.  Antioxidative effect of melatonin in rat brain oxidative stress induced by Adriamycin.

Authors:  P Montilla; I Túnez; M C Muñoz; J V Soria; A López
Journal:  Rev Esp Fisiol       Date:  1997-09

Review 9.  Oxidative-nitrosative stress in hypertension.

Authors:  Nelson Escobales; Maria J Crespo
Journal:  Curr Vasc Pharmacol       Date:  2005-07       Impact factor: 2.719

10.  Prolonged pretreatment with carvedilol prevents 3-nitropropionic acid-induced behavioral alterations and oxidative stress in rats.

Authors:  Puneet Kumar; Anil Kumar
Journal:  Pharmacol Rep       Date:  2008 Sep-Oct       Impact factor: 3.024

View more
  4 in total

1.  Carvedilol attenuates acrylamide-induced brain damage through inhibition of oxidative, inflammatory, and apoptotic mediators.

Authors:  Keyvan Amirshahrokhi; Arezoo Abzirakan
Journal:  Iran J Basic Med Sci       Date:  2022-01       Impact factor: 2.532

Review 2.  A mitochondrial basis for Huntington's disease: therapeutic prospects.

Authors:  J Chakraborty; U Rajamma; K P Mohanakumar
Journal:  Mol Cell Biochem       Date:  2013-12-29       Impact factor: 3.396

Review 3.  Type 2 transglutaminase in Huntington's disease: a double-edged sword with clinical potential.

Authors:  P G Mastroberardino; M Piacentini
Journal:  J Intern Med       Date:  2010-11       Impact factor: 8.989

4.  Comparison of the Effects of 13-cis Retinoic Acid and Melatonin on the Viabilities of SH-SY5Y Neuroblastoma Cell Line.

Authors:  Murat Tosun; Yasemin Soysal; Nuket Gocmen Mas; Hamit Selim Karabekir
Journal:  J Korean Neurosurg Soc       Date:  2015-03-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.